FDA Approves First-Ever Treatment for Deadly Stem Cell Transplant Complication
Omeros' (OMER) Yartemlea becomes the first FDA-approved drug for TA-TMA, a life-threatening complication affecting stem cell transplant patients, with launch planned for January 2026.
